Short-Term Administration of ACTH Improves Plasma Lipid Profile and Renal Function in Kidney Transplant Patients

Transplantation Proceedings

Volumn 38, Issue 5, 2006, Pages 1371-1374

  He, X ^a   Xue, P ^a   Xu, X ^a   Luo, G ^a   Zhou, G ^a   Nilsson Ehle, P ^b   Xu, N ^b  

^a SOOCHOW UNIVERSITY   (China)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CORTICOTROPIN; CREATININE; CYCLOSPORIN; FUROSEMIDE; HIGH DENSITY LIPOPROTEIN; LIPID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TETRACOSACTIDE ZINC PHOSPHATE;

ADULT; ARTICLE; CHEMOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LIVER FUNCTION; MALE; MEDICAL PARAMETERS; MENTAL DISEASE; PRIORITY JOURNAL; SHORT COURSE THERAPY; SIDE EFFECT; STOMACH ULCER; SURGICAL PATIENT; WATER RETENTION;

ADRENOCORTICOTROPIC HORMONE; ADULT; APOLIPOPROTEINS B; CHOLESTEROL, HDL; FEMALE; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; LIPIDS; LIPOPROTEINS, HDL; MALE;

EID: 33745203919     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2006.02.090     Document Type: Article

References (27)

1. Ducloux D., Motte G., and Massy Z.A. Hyperhomocyst(e)inemia as a risk factor after renal transplantation. Ann Transplant 6 (2001) 40
2. Aker S., Ivens K., Grabensee B., et al. Cardiovascular risk factors and diseases after renal transplantation. Int Urol Nephrol 30 (1998) 777
3. Sahadevan M., and Kasiske B.L. Hyperlipidemia in kidney disease. causes and consequences. Curr Opin Nephrol Hypertens 11 (2002) 323
4. Aakhus S., Dahl K., and Wideroe T.E. Cardiovascular disease in stable renal transplant patients in Norway. morbidity and mortality during a 5-yr follow-up. Clin Transplant 18 (2004) 596
5. Satterthwaite R., Aswad S., Sunga V., et al. Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine. Transplantation 65 (1998) 446
6. Galiatsou E., Morris S.T., Jardine A.G., et al. Cardiac and vascular abnormalities in renal transplant patients. differential effects of cyclosporin and azathioprine. J Nephrol 13 (2000) 185
7. Aguilar-Salinas C.A., Diaz-Polanco A., Quintana E., et al. Genetic factors play an important role in the pathogenesis of hyperlipidemia post-transplantation. Am J Kidney Dis 40 (2002) 169
8. Andany M.A., and Kasiske B.L. Dyslipidemia and its management after renal transplantation. J Nephrol 14 Suppl 4 (2001) S81
9. Pirsch J.D., D'Alessandro A.M., Sollinger H.W., et al. Hyperlipidemia and transplantation. etiologic factors and therapy. J Am Soc Nephrol 2 (1992) S238
10. Holdaas H., Fellstrom B., Jardine A.G., et al. Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation. Nephrol Dial Transplant 20 (2005) 974
11. Masterson R., Hewitson T., Leikis M., et al. Impact of statin treatment on 1-year functional and histologic renal allograft outcome. Transplantation 80 (2005) 332
12. Kasiske B., Cosio F.G., Beto J., et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients. a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 4 Suppl 7 (2004) 13
13. Schonder K.S., McKaveney T.P., and Lynch K.J. Retrospective analysis of hyperlipidemia management in a transplant population. Pharmacotherapy 25 (2005) 918
14. Barshes N.R., Goodpastor S.E., and Goss J.A. Pharmacologic immunosuppression. Front Biosci 9 (2004) 411
15. Arnadottir M., Dallongeville J., Nilsson-Ehle P., et al. Effects of short-term treatment with corticotropin on the serum apolipoprotein pattern. Scand J Clin Lab Invest 61 (2001) 301
16. Hardarson A., Sigurdsson G., Olafsdottir E., et al. Adrenocorticotrophic hormone exerts marked lipid-lowering effects in simvastatin-treated patients. J Intern Med 250 (2001) 530
17. Rafnsson A.T., Johannsson M., Olafsson I., et al. Effects of different doses of adrenocorticotrophic hormone on the serum lipoprotein profile in healthy subjects. Basic Clin Pharmacol Toxicol 97 (2005) 86
18. Arnadottir M., Berg A.L., Kronenberg F., et al. Corticotropin-induced reduction of plasma lipoprotein(a) concentrations in healthy individuals and hemodialysis patients. relation to apolipoprotein(a) size polymorphism. Metabolism 48 (1999) 342
19. Arnadottir M., Berg A.L., Dallongeville J., et al. Adrenocorticotrophic hormone lowers serum Lp(a) and LDL cholesterol concentrations in hemodialysis patients. Kidney Int 52 (1997) 1651
20. Berg A.L., and Nilsson-Ehle P. Direct effects of corticotropin on plasma lipoprotein metabolism in man-studies in vivo and in vitro. Metabolism 43 (1994) 90
21. Berg A.L., and Arnadottir M. ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses. Nephrol Dial Transplant 19 (2004) 1305
22. Kasiske B.L. Epidemiology of cardiovascular disease after renal transplantation. Transplantation 72 (2001) S5
23. Berg A.L., Nilsson-Ehle P., and Arnadottir M. Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy. Kidney Int 56 (1999) 1534
24. Berg A.L., and Nilsson-Ehle P. ACTH lowers serum lipids in steroid-treated hyperlipemic patients with kidney disease. Kidney Int 50 (1996) 538
25. Xu N., Ekstrom U., and Nilsson-Ehle P. ACTH decreases the expression and secretion of apolipoprotein B in HepG2 cell cultures. J Biol Chem 276 (2001) 38680
26. Keane W.F. Lipids and the kidney. Kidney Int 46 (1994) 910
27. Neverov N.I., Kaysen G.A., and Tareyeva I.E. Effect of lipid-lowering therapy on the progression of renal disease in nondiabetic nephrotic patients. Contrib Nephrol 120 (1997) 68